Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and FutureRenaud Heine, Carin A. Uyl‐de Groot, Frederick W. Thielen et al.|HemaSphere|2021Cited by 52
Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and ZolgensmaFrederick W. Thielen, Carin A. Uyl‐de Groot, Renaud Heine et al.|Cytotherapy|2022Cited by 26
Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumabRenaud Heine, Carin A. Uyl‐de Groot, Frederick W. Thielen et al.|PLoS ONE|2024Cited by 6
Bridging affordability and sustainability of health innovations via novel pricing, cost-effectiveness, and reimbursement models to improve patient access: The ASCERTAIN projectCarin A. Uyl-de Groot, Eline Aas, N Xander et al.|Health Policy and Technology|2026Cited by 0
Bridging affordability and sustainability of health innovations via novel pricing, cost-effectiveness, and reimbursement models to improve patient access: the ASCERTAIN projectCarin A. Uyl-de Groot, Eline Aas, N Xander et al.|London School of Economics and Political Science Research Online (London School of Economics and Political Science)|2026Cited by 0